Metabolic syndrome pathophysiology and clinical presentation

Toxicologic Pathology

Volumn 37, Issue 1, 2009, Pages 18-20

  Handelsman, Yehuda ^a  

^a Metabolic Institute of America   (United States)

Author keywords

Cardiovascular disease; Diabetes; Dyslipedemia; Hypertension; Insulin resistance; Lifestyle modification; Metabolic syndrome; Nonalcoholic fatty liver disease (NAFLD); Obesity; Polycystic ovarian syndrome (PCOS); Pre diabetes; Sleep and breathing disorder

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; BREATHING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DIABETES MELLITUS; DYSLIPIDEMIA; EPIDEMIC; FATTY LIVER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NEOPLASM; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SLEEP DISORDER; ABDOMINAL FAT; FEMALE; LIFESTYLE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION;

ABDOMINAL FAT; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIFE STYLE; MALE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 62749204395     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623308329288     Document Type: Article

References (25)

1. Alberti, KG, and PZ Zimmet (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 15, 539-553.
2. Chiasson, JL, RG Josse, R Gomis, M Hanefeld, A Karasik, M Laakso, and the STOP-NIDDM Trial Research Group (2002). STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet., 359, 2072-2077.
3. DeFronzo, R (2008). ACT NOW. American Diabetes Association 68th Scientific Sessions: Late Breaking Clinical Studies. Presented at the American Diabetes Association 68th Scientific Sessions: Late Breaking Clinical Studies, June 9, 2008, San Francisco, CA.
4. Del Giudice, ME, IG Fantus, S Ezzat, G McKeown-Eyssen, D Page, and PJ Goodwin (1998). Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat, 47, 110-120.
5. Diabetes Prevention Program Research Group. (2003). Within trial cost-effectiveness of lifestyle intervention or Metformin for the primary prevention of type 2 diabetes. Diabetes Care., 26, 2518-2523.
6. Gerstein, HC, S Yusuf, J Bosch, J Pogue, P Sheridan, N Dinccag, M Hanefeld, B Hoogwerf, M Laakso, V Mohan, J Shaw, B Zinman, and RR Holman (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial [erratum in Lancet. 2006;368:1770]. Lancet., 368, 1096-1105.
7. Einhorn, D, GM Reaven, RH Cobin, E Ford, OP Ganda, Y Handelsman, R Hellman, PS Jellinger, D Kendall, RM Krauss, ND Neufeld, SM Petak, HW Rodbard, JA Seibel, DA Smith, and PW Wilson (2003). ACE Position Statement on the Insulin Resistance Syndrome. Endocr Pract., 9, 240-252.
8. Ford, ES, WH Giles, and WH Dietz (2002). Prevalence of the Metabolic Syndrome Among US Adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA., 287, 356-359.
9. Garber, AJ, Y Handelsman, D Einhorn, DA Bergman, ZT Bloomgarden, V Fonseca, WT Garvey, JR Gavin, III, G Grunberger, ES Horton, PS Jellinger, KL Jones, H Lebovitz, P Levy, DK McGuire, ES Moghissi, and RW Nesto (2008). Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia-When Do the Risks of Diabetes Begin? A Consensus Statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract, 14, 1-14.
10. Grundy, SM, JI Cleeman, SR Daniels, KA Donato, RH Eckel, BA Franklin, DJ Gordon, RM Krauss, PJ Savage, SC Smith, Jr, JA Spertus, and F Costa (2005). Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institutes scientificstatement. Circulation., 18, 1-18.
11. Hanley, AJ, K Williams, A Festa, LE Wagenknecht, RB D'Agostino, Jr, and SM Haffner (2005). Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes, 54, 3140-3147.
12. International Diabetes Federation (IDF). (2008). International Diabetes Federation consensus worldwide definition of the metabolic syndrome.. Available at http://www.idf.org/webdata/docs/IDF-Metasyndrome-definition.pdf. Accessed June 19, 2008.
13. Kahn, BB, and JS Flier (2000). Obesity and insulin resistance. J Clin Invest., 106, 473-481.
14. Lakka, HM, DE Laaksonen, TA Lakka, LK Niskanen, E Kumpusalo, J Tuomilehto, and JT Salonen (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA., 288, 2709-2716.
15. Luu, LCT, and E Ravussin (2008). The other lipids: Ectopic lipids with emphasis on skeletal muscle. Curr Cardiovasc Risk Rep, 1, 15-22.
16. Lorenzo, C, M Okoloise, K Williams, MP Stern, and SM Haffner (2003). The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care., 26, 3153-3156.
17. NCEP-ATP III (2008). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 285, 2486-2497.
18. Reaven, GM (1988). Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
19. Reaven, GM, YD Chen, J Jeppesen, P Maheux, and RM Krauss (1993). Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest., 92, 141-146.
20. Rexrode, KM, VJ Carey, CH Hennekens, EE Walters, GA Colditz, MJ Stampfer, WC Willett, and JE Manson (1998). Abdominal adiposity and coronary heart disease in women. JAMA., 280, 1843-1844.
21. Ridker, PM, JE Buring, NR Cook, and N Rifai (2003). C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation., 107, 391-397.
22. Sironi, AM, A Gastaldelli, A Mari, D Ciociaro, V Positano, E Buzzigoli, S Ghione, S Turchi, M Lombardi, and E Ferrannini (2004). Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension., 44, 127-133.
23. Talbott, EO, DS Guzick, K Sutton-Tyrrell, KP McHugh-Pemu, JV Zborowski, KE Remsberg, and LH Kuller (2000). Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterio Thromb Vasc Biol, 20, 2414-2421.
24. Vgontzas, AN, G Mastorakos, EO Bixler, A Kales, PW Gold, and GP Chrousos (1999). Sleep deprivation effects on the activity of the hypothalamic-pituitary- adrenal and growth axes: potential clinical implications. Clin Endocrinol, 51, 205-215.
25. Young, SE, AG Mainous, 3rd, and M Carnemolla (2006). Hyperinsulinemia and Cognitive Decline in a Middle-Aged Cohort. Diabetes Care, 29, 2688-2693.